<DOC>
	<DOCNO>NCT01973842</DOCNO>
	<brief_summary>The present study aim investigate whether dosage GnRH agonist use trigger final oocyte maturation affect maturity oocytes retrieve high risk OHSS patient undergo ovarian stimulation IVF use GnRH antagonist recombinant FSH .</brief_summary>
	<brief_title>Evaluation Optimal Dose GnRH Agonist Triggering Final Oocyte Maturation High Risk OHSS Patients</brief_title>
	<detailed_description>Three different dos GnRH agonist ( 0.1mg , 0.2mg 0.4 mg ) use randomly trigger final oocyte maturation . The primary outcome measure percentage mature oocytes retrieve . Secondary outcome include : number oocytes retrieve , oocyte recovery rate ( number oocytes retrieved/ number follicle &gt; 11mm diameter day trigger ) , fertilization rate OHSS occurrence . Serum LH , FSH , E2 , PRG level assess 8-36 hour follow agonist administration day 3-4-7-10 trigger final oocyte maturation .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<criteria>Patients undergo ovarian stimulation IVF use GnRH antagonist protocol Age &lt; 40 year Anticipated high ovarian response Endometriosis &gt; grade II One ovary</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>GnRH agonist</keyword>
	<keyword>OHSS</keyword>
	<keyword>Triggering final oocyte maturation</keyword>
</DOC>